Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

NCT04479852 is registered in ClinicalTrials.gov with Sirtsei Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04479852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04479852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2020
Completion date
August 9, 2022
Enrollment
319 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder